Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice (Q43109145)

14 November 2017

Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice (English)

1 reference

14 November 2017

1 reference

8

Toshikazu Yoshikawa

1 reference

14 November 2017

Kanji Yamaguchi

1

1 reference

14 November 2017

Yoshito Itoh

2

1 reference

14 November 2017

Chihiro Yokomizo

3

1 reference

14 November 2017

Takeshi Nishimura

4

1 reference

14 November 2017

Toshihisa Niimi

5

1 reference

14 November 2017

Hideki Fujii

6

1 reference

14 November 2017

Takeshi Okanoue

7

1 reference

14 November 2017

5 April 2010

1 reference

14 November 2017

Laboratory Investigation

1 reference

14 November 2017

90

1 reference

14 November 2017

8

1 reference

14 November 2017

1169-1178

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2010.75

14 November 2017

0 references

cites work

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

gp130 receptor ligands as potential therapeutic targets for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

The role of interleukin-6 in mucosal IgA antibody responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Ischemic preconditioning protects the steatotic mouse liver against reperfusion injury: an ATP dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Tocilizumab: a review of its use in the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Interleukin-6-deficient mice develop mature-onset obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

Adipokines and cytokines in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, Type 2 diabetes, and NASH

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

Characterization of anti-mouse interleukin-6 receptor antibody

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2010.75

7 January 2021

10.1038/LABINVEST.2010.75

Identifiers

DOI

1 reference

14 November 2017

1 reference